Tina Vilsbll

List of Publications by Citations

274 papers	15,996 citations	56 h-index	122 g-index
314 ext. papers	19,011 ext. citations	6.1 avg, IF	6.7 L-index

#	Paper	IF	Citations
274	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*, **2016**, 375, 1834-1844	59.2	2547
273	Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. *Diabetes*, **2001**, 50, 609-13	0.9	747
272	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. *BMJ, The*, **2012**, 344, d7771	5.9	575
271	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*, **2019**, 381, 841-851	59.2	567
270	Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. *Diabetologia*, **2002**, 45, 1111-9	10.3	400
269	The incretin system and its role in type 2 diabetes mellitus. *Molecular and Cellular Endocrinology*, **2009**, 297, 127-36	4.4	397
268	Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 2706-13	5.6	397
267	Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. *Diabetes Care*, **2007**, 30, 1608-10	14.6	376
266	Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 220-4	5.6	338
265	Incretins, insulin secretion and Type 2 diabetes mellitus. *Diabetologia*, **2004**, 47, 357-366	10.3	331
264	Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. *Regulatory Peptides*, **2003**, 114, 115-21		315
263	Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. *Diabetologia*, **2009**, 52, 199-207	10.3	296
262	Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2010**, 12, 167-77	6.7	262
261	Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?. *Diabetes*, **2007**, 56, 1951-9	0.9	251
260	Recovery of gut microbiota of healthy adults following antibiotic exposure. *Nature Microbiology*, **2018**, 3, 1255-1265	26.6	246
259	Role of gastrointestinal hormones in postprandial reduction of bone resorption. *Journal of Bone and Mineral Research*, **2003**, 18, 2180-9	6.3	233
258	Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. *Diabetes*, **2011**, 60, 3103-9	0.9	208

257	The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. *Diabetes*, **2010**, 59, 1765-70	0.9	194
256	Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). *Diabetes Care*, **2014**, 37, 2926-33	14.6	189
255	Glucagon-like peptide 1 in health and disease. *Nature Reviews Endocrinology*, **2018**, 14, 390-403	15.2	187
254	Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. *Diabetes Care*, **2011**, 34 Suppl 2, S251-7	14.6	185
253	Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. *Diabetic Medicine*, **2008**, 25, 152-6	3.5	175
252	The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 4897-903	5.6	175
251	Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. *Diabetologia*, **2013**, 56, 965-72	10.3	167
250	Impaired regulation of the incretin effect in patients with type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 737-45	5.6	157
249	Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. *Diabetic Medicine*, **2008**, 25, 1129-31	3.5	149
248	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. *Diabetologia*, **2014**, 57, 1919-26	10.3	129
247	Glucagon-like peptide-1, glucose homeostasis and diabetes. *Trends in Molecular Medicine*, **2008**, 14, 161-8	11.5	128
246	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. *PLoS ONE*, **2016**, 11, e0166125	3.7	126
245	Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 447-53	5.6	124
244	Incretin-based therapies: viewpoints on the way to consensus. *Diabetes Care*, **2009**, 32 Suppl 2, S223-31	14.6	123
243	The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. *American Journal of Physiology - Endocrinology and Metabolism*, **2011**, 300, E1038-46	6	118
242	The effect of glucagon-like peptide 1 on cardiovascular risk. *Nature Reviews Cardiology*, **2012**, 9, 209-22	14.8	117
241	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. *Diabetes, Obesity and Metabolism*, **2018**, 20, 889-897	6.7	114
240	Evidence of Extrapancreatic Glucagon Secretion in Man. *Diabetes*, **2016**, 65, 585-97	0.9	102

239	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. *European Journal of Internal Medicine*, **2014**, 25, 407-14	3.9	101
238	Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. *Diabetes Care*, **2013**, 36, 3346-52	14.6	101
237	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. *European Journal of Endocrinology*, **2014**, 170, 529-38	6.5	101
236	Glucagon antagonism as a potential therapeutic target in type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2011**, 13, 965-71	6.7	99
235	Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. *Molecular Systems Biology*, **2019**, 15, e8793	12.2	94
234	Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E2325-9	5.6	86
233	The effects of glucagon-like peptide-1 on the beta cell. *Diabetes, Obesity and Metabolism*, **2009**, 11 Suppl 3, 11-8	6.7	85
232	Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. *Diabetologia*, **2015**, 58, 2254-8	10.3	83
231	Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis. *Diabetes, Obesity and Metabolism*, **2016**, 18, 300-5	6.7	83
230	Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 4679-87	5.6	82
229	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*, **2017**, 74, 719-728	14.5	80
228	Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. *Expert Opinion on Investigational Drugs*, **2007**, 16, 231-7	5.9	77
227	Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 3002-9	5.6	72
226	Glucagon and type 2 diabetes: the return of the alpha cell. *Current Diabetes Reports*, **2014**, 14, 555	5.6	71
225	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. *Diabetes*, **2019**, 68, 906-917	0.9	70
224	Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. *Diabetologia*, **2018**, 61, 284-294	10.3	66
223	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. *American Journal of Physiology - Renal Physiology*, **2019**, 316, G462-G472	5.1	63
222	Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism. *PLoS ONE*, **2015**, 10, e0142352	3.7	61

221	Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2017**, 19, 906-908	6.7	59
220	The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. *Mayo Clinic Proceedings*, **2018**, 93, 217-239	6.4	57
219	Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E418-26	5.6	57
218	Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. *Diabetes Care*, **2014**, 37, 1797-805	14.6	56
217	No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. *Diabetic Medicine*, **2001**, 18, 144-9	3.5	56
216	Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. *Diabetes, Obesity and Metabolism*, **2016**, 18, 571-80	6.7	55
215	Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. *American Journal of Physiology - Endocrinology and Metabolism*, **2010**, 298, E832-7	6	53
214	GIP(3-30)NH is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. *Diabetologia*, **2018**, 61, 413-423	10.3	52
213	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. *Diabetologia*, **2019**, 62, 665-675	10.3	51
212	Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 4541-52	5.6	51
211	Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. *Diabetes*, **2015**, 64, 72-8	0.9	49
210	Patients with psoriasis are insulin resistant. *Journal of the American Academy of Dermatology*, **2015**, 72, 599-605	4.5	48
209	The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. *Regulatory Peptides*, **2006**, 137, 168-72		48
208	Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. *Journal of Diabetes and Its Complications*, **2017**, 31, 918-927	3.2	46
207	Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 288-294	5.6	46
206	Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. *European Journal of Endocrinology*, **2014**, 171, 407-19	6.5	46
205	The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. *Regulatory Peptides*, **2007**, 144, 123-30		46
204	Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. *BMJ Open*, **2014**, 4, e005325	3	44

203	Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. *JCI Insight*, **2018**, 3,	9.9	44
202	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. *Diabetes, Obesity and Metabolism*, **2020**, 22, 442-451	6.7	44
201	Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. *Frontiers in Endocrinology*, **2018**, 9, 649	5.7	43
200	Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. *European Journal of Endocrinology*, **2013**, 169, 187-201	6.5	42
199	The alpha-cell as target for type 2 diabetes therapy. *Review of Diabetic Studies*, **2011**, 8, 369-81	3.6	42
198	Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. *Diabetes, Obesity and Metabolism*, **2016**, 18, 955-61	6.7	42
197	Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. *EBioMedicine*, **2016**, 7, 112-20	8.8	42
196	Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. *Diabetes, Obesity and Metabolism*, **2019**, 21, 293-302	6.7	40
195	Exenatide: pharmacokinetics, clinical use, and future directions. *Expert Opinion on Pharmacotherapy* , **2017**, 18, 555-571	4	39
194	Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. *Diabetologia*, **2014**, 57, 1720-5	10.3	39
193	Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. *American Journal of Physiology - Renal Physiology*, **2016**, 310, G43-51	5.1	38
192	Incretin-based therapy of type 2 diabetes mellitus. *Current Protein and Peptide Science*, **2009**, 10, 46-55	2.8	37
191	Supportive and non-supportive interactions in families with a type 2 diabetes patient: an integrative review. *Diabetology and Metabolic Syndrome*, **2017**, 9, 57	5.6	36
190	Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. *Diabetes Care*, **2000**, 23, 807-12	14.6	36
189	GLP-1 and Amylin in the Treatment of Obesity. *Current Diabetes Reports*, **2016**, 16, 1	5.6	35
188	FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest. *Molecular Metabolism*, **2018**, 11, 96-103	8.8	34
187	Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3. *Diabetes*, **2014**, 63, 2838-44	0.9	34
186	Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. *International Journal of Obesity*, **2015**, 39, 1651-4	5.5	33

185	Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. *Diabetes Care*, **2017**, 40, 109-116	14.6	33
184	Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment. *Basic and Clinical Pharmacology and Toxicology*, **2016**, 118, 168-70	3.1	32
183	Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. *Journal of Internal Medicine*, **2016**, 279, 485-93	10.8	32
182	Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. *American Journal of Physiology - Renal Physiology*, **2018**, 314, G91-G96	5.1	29
181	Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. *Diabetes and Vascular Disease Research*, **2016**, 13, 321-30	3.3	28
180	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 880-893	18.1	27
179	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 2953-2960	5.6	26
178	Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2016**, 18, 40-8	6.7	26
177	The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism* , **2018**, 20, 362-369	6.7	26
176	Cardiovascular safety and benefits of GLP-1 receptor agonists. *Expert Opinion on Drug Safety*, **2017**, 16, 351-363	4.1	25
175	Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies. *Basic and Clinical Pharmacology and Toxicology*, **2018**, 122, 559-569	3.1	25
174	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. *Diabetes, Obesity and Metabolism*, **2018**, 20, 508-519	6.7	25
173	Use of antibiotics in childhood and risk of Type 1 diabetes: a population-based case-control study. *Diabetic Medicine*, **2017**, 34, 272-277	3.5	25
172	Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function. *International Journal of Cardiology*, **2016**, 221, 114-21	3.2	24
171	IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. *Diabetes Therapy*, **2015**, 6, 573-591	3.6	24
170	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	23
169	Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial. *Journal of the European Academy of Dermatology and Venereology*, **2015**, 29, 555-9	4.6	23
168	Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer. *Expert Opinion on Drug Safety*, **2015**, 14, 171-80	4.1	23

167	Dialysis-Requiring Acute Kidney Injury in Denmark 2000-2012: Time Trends of Incidence and Prevalence of Risk Factors-A Nationwide Study. *PLoS ONE*, **2016**, 11, e0148809	3.7	23
166	Investigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 6403-6416	5.6	21
165	Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2017**, 19, 172-180	6.7	21
164	Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People. *Diabetes Care*, **2020**, 43, 411-417	14.6	21
163	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 2076-83	5.6	20
162	Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. *Diabetes, Obesity and Metabolism*, **2012**, 14 Suppl 2, 41-9	6.7	20
161	Emerging GLP-1 receptor agonists. *Expert Opinion on Emerging Drugs*, **2011**, 16, 607-18	3.7	20
160	Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 4153-4162	5.6	19
159	The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2015**, 309, R544-51	3.2	19
158	The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects. *European Journal of Endocrinology*, **2014**, 171, 353-62	6.5	19
157	The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2009**, 23, 453-62	6.5	19
156	One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. *Acta Psychiatrica Scandinavica*, **2019**, 139, 26-36	6.5	19
155	Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1040-1044	6.7	18
154	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 313-324	18.1	18
153	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	18
152	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. *Diabetes Care*, **2020**, 43, 588-596	14.6	18
151	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. *Cell Reports*, **2017**, 21, 1452-1460	10.6	18
150	Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus. *BioDrugs*, **2008**, 22, 251-7	7.9	18

149	A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. *Diabetes Technology and Therapeutics*, **2017**, 19, 255-264	8.1	17
148	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. *Regulatory Peptides*, **2010**, 163, 96-101		17
147	Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia. *Medical Hypotheses*, **2016**, 86, 100-3	3.8	17
146	Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes. *European Heart Journal Cardiovascular Imaging*, **2018**, 19, 1034-1041	4.1	16
145	Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial. *BMJ Open*, **2018**, 8, e019562	3	16
144	Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis. *Diabetes*, **2020**, 69, 1090-1099	0.9	15
143	Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2016**, 64, 908-15	13.4	15
142	Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity. *Diabetes, Obesity and Metabolism*, **2018**, 20, 2557-2564	6.7	15
141	The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2017**, 19, 189-199	6.7	15
140	Dietary habits and adherence to dietary recommendations in patients with type 1 and type 2 diabetes compared with the general population in Denmark. *Nutrition*, **2019**, 61, 49-55	4.8	15
139	Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. *Frontiers in Endocrinology*, **2020**, 11, 617400	5.7	15
138	Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes. *Cardiovascular Diabetology*, **2016**, 15, 137	8.7	14
137	Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial. *Canadian Journal of Diabetes*, **2018**, 42, S42	2.1	14
136	Ghrelin secretion in humans - a role for the vagus nerve?. *Neurogastroenterology and Motility*, **2018**, 30, e13295	4	13
135	Cardiovascular biomarkers in clinical studies of type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1350-1360	6.7	13
134	Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus. *Regulatory Peptides*, **2013**, 186, 104-7		13
133	Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis. *Journal of Internal Medicine*, **2015**, 278, 660-70	10.8	13
132	Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. *BMJ Open*, **2014**, 4, e004227	3	13

131	Trends in One-Year Outcomes of Dialysis-Requiring Acute Kidney Injury in Denmark 2005-2012: A Population-Based Nationwide Study. *PLoS ONE*, **2016**, 11, e0159944	3.7	13
130	On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus. *Danish Medical Bulletin*, **2004**, 51, 364-70		13
129	Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1214-1222	6.7	12
128	Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation. *Peptides*, **2015**, 71, 229-31	3.8	12
127	Hypoglycaemia and cardiac arrhythmias in diabetes. *Therapeutic Advances in Endocrinology and Metabolism*, **2020**, 11, 2042018820911803	4.5	12
126	Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response. *Nutrition, Metabolism and Cardiovascular Diseases*, **2017**, 27, 1123-1129	4.5	12
125	Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. *Expert Opinion on Drug Safety*, **2017**, 16, 387-396	4.1	11
124	Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?. *Current Diabetes Reports*, **2017**, 17, 128	5.6	11
123	Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1506-1512	6.7	11
122	Differential time responses in inflammatory and oxidative stress markers after a marathon: An observational study. *Journal of Sports Sciences*, **2020**, 38, 2080-2091	3.6	11
121	Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1623-1631	6.7	11
120	Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. *Clinical Drug Investigation*, **2016**, 36, 293-303	3.2	11
119	Review: DPP IV inhibitors - current evidence and future directions. *British Journal of Diabetes and Vascular Disease*, **2007**, 7, 69-74		11
118	GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH. *Bone*, **2020**, 130, 115079	4.7	11
117	Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance. *International Journal of Clinical Practice*, **2021**, 75, e13731	2.9	11
116	Identification and Metabolic Profiling of a Novel Human Gut-derived LEAP2 Fragment. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e966-e981	5.6	11
115	Pancreatic Amylase and Lipase Plasma Concentrations Are Unaffected by Increments in Endogenous GLP-1 Levels Following Liquid Meal Tests. *Diabetes Care*, **2015**, 38, e71-2	14.6	10
114	Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. *European Journal of Endocrinology*, **2015**, 173, 205-15	6.5	10

113	Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study. *Diabetes, Obesity and Metabolism*, **2016**, 18, 1283-1287	6.7	10
112	Risk stratification by endocrinologists of patients with type 2 diabetes in a Danish specialised outpatient clinic: a cross-sectional study. *BMC Health Services Research*, **2016**, 16, 124	2.9	10
111	Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis. *Journal of Gastroenterology and Hepatology (Australia)*, **2015**, 30, 1522-8	4	10
110	Sevelamer in a diabetologistR perspective: a phosphate-binding resin with glucose-lowering potential. *Diabetes, Obesity and Metabolism*, **2015**, 17, 116-20	6.7	10
109	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2010**, 3, 155-63	3.4	10
108	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. *Diabetes*, **2019**, 68, 64-OR	0.9	10
107	Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA). *Diabetes Care*, **2020**, 43, 2025-2033	14.6	10
106	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. *Bone*, **2020**, 140, 115553	4.7	10
105	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. *Metabolic Syndrome and Related Disorders*, **2018**, 16, 530-536	2.6	10
104	Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 2042-2049	5.6	10
103	The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. *BMJ Open*, **2017**, 7, e014728	3	9
102	Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect. *Diabetologia*, **2017**, 60, 1344-1353	10.3	9
101	The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. *Expert Opinion on Pharmacotherapy*, **2019**, 20, 501-510	4	9
100	Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control. *Peptides*, **2018**, 101, 32-43	3.8	9
99	Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake. *CPT: Pharmacometrics and Systems Pharmacology*, **2016**, 5, 692-700	4.5	9
98	Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans. *CPT: Pharmacometrics and Systems Pharmacology*, **2018**, 7, 603-612	4.5	9
97	Alcohol consumption among patients with diabetes: a survey-based cross-sectional study of Danish adults with diabetes. *Scandinavian Journal of Public Health*, **2016**, 44, 517-24	3	9
96	Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2019**, 21, 736-740	6.7	9

95	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. *American Journal of Physiology - Endocrinology and Metabolism*, **2017**, 313, E284-E291	6	8
94	Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). *Diabetes, Obesity and Metabolism*, **2020**, 22, 1339-1347	6.7	8
93	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 4377-4384	5.6	8
92	Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes. *Journal of Clinical Pharmacology*, **2016**, 56, 340-8	2.9	8
91	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. *CNS Spectrums*, **2019**, 24, 441-452	1.8	8
90	Patient Assessment of Family Function, Glycemic Control and Quality of Life in Adult Patients With Type 2 Diabetes and Incipient Complications. *Canadian Journal of Diabetes*, **2019**, 43, 193-200	2.1	8
89	GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1 Mutation Carriers. *Diabetes*, **2020**, 69, 1989-2002	0.9	7
88	Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers. *Diabetes Care*, **2018**, 41, 1260-1267	14.6	7
87	Shared care management of patients with type 2 diabetes across the primary and secondary healthcare sectors: study protocol for a randomised controlled trial. *Trials*, **2016**, 17, 277	2.8	7
86	Retinal vascular and structural dynamics during acute hyperglycaemia. *Acta Ophthalmologica*, **2015**, 93, 697-705	3.7	7
85	The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. *BMJ Open*, **2013**, 3, e003834	3	7
84	GIPR involvement in the pathophysiology of type 2 diabetes. *Peptides*, **2020**, 125, 170178	3.8	7
83	A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. *Drugs*, **2021**, 81, 1003-1030	12.1	7
82	Glucose metabolism in patients with psoriasis. *British Journal of Dermatology*, **2019**, 180, 264-271	4	7
81	Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. *Drugs*, **2020**, 80, 147-165	12.1	6
80	Liraglutide: a human GLP-1 analog for Type 2 diabetes. *Therapy: Open Access in Clinical Medicine*, **2009**, 6, 199-207		6
79	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. *European Journal of Endocrinology*, **2021**, 184, 383-394	6.5	6
78	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. *Diabetes, Obesity and Metabolism*, **2021**, 23, 2058-2066	6.7	6

77	Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 168-173	5.6	6
76	Plasma YKL-40 during pregnancy and gestational diabetes mellitus. *Journal of Reproductive Immunology*, **2015**, 112, 68-72	4.2	5
75	Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent. *Neurochemistry International*, **2020**, 138, 104772	4.4	5
74	The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. *Expert Review of Endocrinology and Metabolism*, **2011**, 6, 513-525	4.1	5
73	Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial. *Diabetes*, **2018**, 67, 1084-P	0.9	5
72	The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition. *Diabetes*, **2020**, 69, 2619-2629	8.9	5
71	Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial. *BMJ Open*, **2018**, 8, e022517	3	5
70	Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic. *Diabetic Medicine*, **2021**, 38, e14655	3.5	5
69	Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. *Diabetes Care*, **2019**, 42, 1464-1472	14.6	4
68	Gluco-metabolic effects of oral and intravenous alcohol administration in men. *Endocrine Connections*, **2019**, 8, 1372-1382	3.5	4
67	Effects of endogenous GIP in patients with type 2 diabetes. *European Journal of Endocrinology*, **2021**, 185, 33-45	6.5	4
66	Glucagon-like peptide-1 (GLP-1) analogues: A potential new treatment for alcohol use disorder?. *Nordic Journal of Psychiatry*, **2016**, 70, 561-2	2.3	4
65	An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. *Diabetes, Obesity and Metabolism*, **2021**, 23 Suppl 1, 17-35	6.7	4
64	How glucagon-like peptide 1 receptor agonists work. *Endocrine Connections*, **2021**, 10, R200-R212	3.5	4
63	Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. *Diabetes, Obesity and Metabolism*, **2021**, 23 Suppl 3, 40-52	6.7	4
62	Premature explantation of an EndoBarrier gastrointestinal liner because of sleeve invagination. *Endoscopy*, **2015**, 47 Suppl 1 UCTN, E275-6	3.4	3
61	Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1937-1943	6.7	3
60	Disturbed postprandial glucose metabolism and gut hormone responses in non-diabetic patients with psoriasis. *British Journal of Dermatology*, **2016**, 175, 1085-1088	4	3

59	Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes. *ELife*, **2021**, 10,	8.9	3
58	Experience of family function, family involvement, and self-management in adult patients with type 2 diabetes: A thematic analysis. *Journal of Advanced Nursing*, **2020**, 76, 621-631	3.1	3
57	Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. *Journal of the Endocrine Society*, **2020**, 4, bvaa097	0.4	3
56	Expression of Cholecystokinin and its Receptors in the Intestinal Tract of Type 2 Diabetes Patients and Healthy Controls. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 2164-2170	5.6	3
55	Management of people with Type 2 diabetes shared between a specialized outpatient clinic and primary health care is noninferior to management in a specialized outpatient clinic: a randomized, noninferiority trial. *Diabetic Medicine*, **2019**, 36, 854-861	3.5	3
54	Survival of patients with and without diabetes following out-of-hospital cardiac arrest: A nationwide Danish study. *European Heart Journal: Acute Cardiovascular Care*, **2020**, 9, 599-607	4.3	3
53	Changes in oxidative nucleic acid modifications and inflammation following one-week treatment with the bile acid sequestrant sevelamer: Two randomised, placebo-controlled trials. *Journal of Diabetes and Its Complications*, **2020**, 34, 107446	3.2	3
52	No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course. *BMC Endocrine Disorders*, **2018**, 18, 60	3.3	3
51	Hepatic microbiome in healthy lean and obese humans. *JHEP Reports*, **2021**, 3, 100299	10.3	3
50	LEAP2 reduces postprandial glucose excursions and food intake in healthy men.. *Cell Reports Medicine*, **2022**, 3, 100582	18	3
49	Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study.. *Cardiovascular Diabetology*, **2021**, 20, 241	8.7	3
48	Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose. *Basic and Clinical Pharmacology and Toxicology*, **2017**, 121, 290-297	3.1	2
47	Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain-Reply. *JAMA Psychiatry*, **2017**, 74, 1173-1174	14.5	2
46	An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. *International Journal of Cardiology*, **2019**, 289, 119-124	3.2	2
45	Gut Mucosal Gene Expression and Metabolic Changes After Roux-en-Y Gastric Bypass Surgery. *Obesity*, **2020**, 28, 2163-2174	8	2
44	The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. *Diabetologia*, **2020**, 63, 1285-1298	10.3	2
43	Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial. *BMJ Open*, **2018**, 8, e021861	3	2
42	Glucagon and the gut hormones GLP-1 and oxyntomodulin increase resting energy expenditure in man. *Regulatory Peptides*, **2012**, 177, S15-S16		2

41	On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes. *Endocrine Connections*, **2014**, 3, 193-9	3.5	2
40	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. *Diabetes*, **2020**, 69, 89-LB	0.9	2
39	No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect. *Endocrine Connections*, **2020**, 9, 1221-1232	3.5	2
38	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	2
37	One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
36	Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls. *European Journal of Endocrinology*, **2021**, 185, 343-353	6.5	2
35	Prognostic Value of Early Systolic Lengthening by Strain Imaging in Type 2 Diabetes. *Journal of the American Society of Echocardiography*, **2021**, 34, 127-135	5.8	2
34	Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. *Diabetes*, **2021**, 70, 1347-1356	0.9	2
33	Therapy: Liraglutide - preventing or postponing T2DM diagnosis?. *Nature Reviews Endocrinology*, **2017**, 13, 320-322	15.2	1
32	Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. *Expert Review of Clinical Pharmacology*, **2015**, 8, 273-82	3.8	1
31	The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men. *Alcohol*, **2020**, 87, 29-37	2.7	1
30	Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1639-1647	6.7	1
29	Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial. *Diabetes, Obesity and Metabolism*, **2020**, 22, 957-968	6.7	1
28	Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. *BMC Research Notes*, **2014**, 7, 326	2.3	1
27	A 25-year-old woman with type 2 diabetes and liver disease. *Case Reports in Gastroenterology*, **2014**, 8, 398-403	1	1
26	Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin for patients with Type 2 diabetes mellitus. *Expert Review of Endocrinology and Metabolism*, **2008**, 3, 13-19	4.1	1
25	Effectiveness and acceptability of a pragmatic exercise intervention for patients with type 2 diabetes in specialized care.. *Diabetes Research and Clinical Practice*, **2021**, 183, 109176	7.4	1
24	Secretion of parathyroid hormone may be coupled to insulin secretion in humans. *Endocrine Connections*, **2020**, 9, 747-754	3.5	1

23	Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study. *Clinical and Translational Gastroenterology*, **2020**, 11, e00257	4.2	1
22	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. *Schizophrenia Bulletin Open*, **2020**, 1,	2.2	1
21	Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. *Nutrients*, **2020**, 12,	6.7	1
20	Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial. *Psychiatry Research*, **2021**, 296, 113670	9.9	1
19	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. *Cardiovascular Diabetology*, **2022**, 21, 50	8.7	1
18	Normal insulin sensitivity, glucose tolerance, gut incretin and pancreatic hormone responses in adults with atopic dermatitis. *Diabetes, Obesity and Metabolism*, **2020**, 22, 2161-2169	6.7	0
17	In patients with controlled acromegaly, indices of glucose homeostasis correlate with IGF-1 levels rather than with type of treatment. *Clinical Endocrinology*, **2021**, 95, 65-73	3.4	0
16	Pancreatic polypeptide: A potential biomarker of glucose-dependent insulinotropic polypeptide receptor activation in vivo. *Diabetic Medicine*, **2021**, 38, e14592	3.5	0
15	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. *European Journal of Endocrinology*, **2021**, 185, 23-32	6.5	0
14	Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption. *BMJ Open*, **2021**, 11, e044711	3	0
13	The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. *Diabetologia*, **2021**, 64, 2425-2431	10.3	0
12	Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial. *Diabetes, Obesity and Metabolism*, **2022**, 24, 142-147	6.7	0
11	Transforming Motivation for Exercise in a Safe and Kind Environment—A Qualitative Study of Experiences among Individuals with Type 2 Diabetes. *International Journal of Environmental Research and Public Health*, **2022**, 19, 6091	4.6	0
10	The Role of Glucagon-like Receptor-1 Agonists in the Metabolic Syndrome **2013**, 165-183		
9	Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake.. *Obesity Surgery*, **2022**, 32, 1385	3.7	
8	Dapagliflozin plus Saxagliptin Shows Noninferior A1C Reduction vs. Insulin Glargine in Patients with Type 2 Diabetes Inadequately Controlled by Metformin With or Without Sulfonylurea. *Diabetes*, **2018**, 67, 260-OR	0.9	
7	1186-P: Lean Women with Polycystic Ovary Syndrome and Insulin Resistance Have Normal Incretin Effect, which Is Unaffected by Metformin Therapy. *Diabetes*, **2019**, 68, 1186-P	0.9	
6	350-OR: A Novel Long-Acting GLP-1 Agonist (GL0034) Demonstrates Remarkable Efficacy on HbA1c, Weight Loss, and Triglycerides in a Model of Type 2 Diabetes, the db/db Mouse. *Diabetes*, **2020**, 69, 350-OR	0.9	

5	2187-PUB: Identifying Risk Predictors for Gastrointestinal Adverse Events with Once-Weekly Semaglutide. *Diabetes*, **2020**, 69, 2187-PUB	0.9
4	Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia. *CNS Spectrums*, **2020**, 1-8	1.8
3	The Danish comorbidity in liver transplant recipients study (DACOLT): a non-interventional prospective observational cohort study. *BMC Gastroenterology*, **2021**, 21, 145	3
2	Response to Letter to the Editor from McKee and McGill: "Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring". *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e4307-e4308	5.6
1	Non-Insulin Parenteral Therapies **2016**, 455-470	